Essential hypertension
Conditions
Sponsors
Novartis Pharma K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients that have successfully completed Core study (JapicCTI-101273) and who, as judged by the investigator, are able to continue in the open-label extension. 2. Ability to communicate and comply with all study requirements and demonstrate good medication compliance (>=80% compliance rate) during Core study.
Exclusion criteria
Exclusion criteria: 1. Patients who did not complete Core study. 2. Presence of significant protocol violation in Core study. 3. Patients who are deemed to be unable to comply with the protocol by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability The primary assessment for safety and tolerability is the reporting of any adverse events and serious adverse events (SAE) including death. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean sitting diastolic blood pressure and mean sitting systolic blood pressure Summary statistics for the post-baseline and the change-from-baseline measurements will be provided by timepoint in mean sitting diastolic blood pressure, mean sitting systolic blood pressure. | — |
Outcome results
None listed